Ascendis Pharma A/S
corporate_fare Company Profile
Ascendis Pharma A/S (NASDAQ:ASND) is a publicly traded company in the Life Sciences sector. Wiseek monitors ASND SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Pivotal Trial: TransCon CNP Shows Continued 2-Year Improvements in Achondroplasia, Well-Tolerated
- Ascendis Pharma Completes $187.5M Sale of Rare Pediatric Disease Priority Review Voucher
- TransCon PTH Shows Sustained Efficacy, Safety Through 3.5 Years in Phase 3 Hypoparathyroidism Trial
- Long-Term Data: TransCon PTH Sustains Efficacy for 5 Years in Hypoparathyroidism
- EVP Sells All Direct Holdings for $4.6M Amidst Positive Company News
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for ASND, detected from its recent SEC filings · based on capital-structure filings through 2026-04-21.
Redemption of Convertible Notes · Triggered by Strong Stock Performance
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
ASND files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.